Driving Efficiencies In New Biologics Development And Manufacturing: The Power Of Platform Processes And Digital Access

Unlocking the potential of next-generation therapeutics requires extending the boundaries of both expression system technology and process development and manufacturing. Versatile and scalable platform technologies are one element of that initiative. Another is production digitization that enhances data integrity and transparency in customer information access.

KBI Biopharma’s SUREmAb™️ offering, specific to monoclonal antibodies and based on the SUREtechnology™️ platform, is an example of such an advancement. Programs that run through SUREmAb progress from transfection to a high-performing research cell bank (RCB) in as little as 9 weeks, or directly to drug substance release in as few as 11 months.
Similarly, the use of PUREplatform™️, an E. coli expression system, can lead to approximately fivefold lower COGS plus faster development timelines. As part of PUREplatform, KBI Biopharma’s proprietary E. coli strain, PUREcoli™️, has been optimized to promote molecular metabolism regardless of modality.

Finally, PROGRAMview™️ is a software application that bridges the data access gap between the company’s laboratories and program stakeholders, easing management of the voluminous and complex data generated every day when developing and manufacturing transformative products.